ArticleNAM journal2025
Exploring the Mechanisms of EDCs-Induced Metabolic Disorders in Humans Using Network Toxicology and Molecular Docking.
Article in NAM journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to investigate the potential mechanisms by which EDCs, recognized as emerging pollutants, induce metabolic disorders leading to metabolic diseases in humans. Methods: Network toxicology and molecular docking techniques were employed to elucidate the molecular mechanisms underlying EDCs-induced pathogenesis of the six diseases. Potential targets associated with EDCs and these diseases were identified using databases such as PubChem, ChEMBL, Super-PRED, GeneCards, OMIM, and TTD. STRING analysis and Cytoscape software were further utilized to determine core targets most significantly linked to these metabolic disorders. GO and KEGG pathway enrichment analyses were performed on the core targets using the DAVID database. Finally, molecular docking was conducted to validate the binding affinities between EDCs and core target proteins. Results: EDCs may potentially induce metabolic disorders by modulating cellular expression, influencing apoptosis and proliferation, and regulating related signaling pathways. Notably, a close interrelationship was observed among lipid metabolism disorders and atherosclerosis, Alzheimer's disease, type 2 diabetes mellitus, osteoporosis, hyperuricemia, and non-alcoholic fatty liver disease. Conclusion: This study provides novel insights into the mechanisms through which EDCs induce metabolic diseases in humans and highlights correlations among distinct disorders, thereby establishing a theoretical foundation for disease prevention and therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.